Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 13/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498723 | 1.00 | P2RY6 (0.66) | P2RY6P2RY2DNPH1P2RY4 | |
| Cyanide SCHEMBL29185235 | 0.97 | P2RY6 (0.63) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL4076682 | 0.90 | P2RY2 (0.54) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL2609977 | 0.89 | P2RY6 (0.51) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL12714926 | 0.87 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL15065276 | 0.87 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL17979616 | 0.87 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL14946379 | 0.87 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL14929299 | 0.87 | DNPH1 (0.81) | P2RY6P2RY2DNPH1P2RY4 | |
| SCHEMBL15065277 | 0.87 | P2RY6 (0.72) | P2RY6P2RY2DNPH1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484760-B1 | METHOD FOR PREPARING aRNA. | TORAY INDUSTRIES (JP) | 2015-10-14 | — | — | EP | claimed |
| US-20150191781-A1 | RANDOM-PRIMED TRANSCRIPTASE IN-VITRO TRANSCRIPTION METHOD FOR RNA AMPLIFICATION | ROSETTA INPHARMATICS, INC. | 2015-07-09 | — | — | US | claimed |
| EP-2484760-A1 | METHOD FOR PREPARING aRNA AND METHOD FOR ASSAYING GENE EXPRESSION | Toray Industries, Inc. (JP) | 2012-08-08 | — | — | EP | claimed |
| US-20120196768-A1 | METHOD FOR PREPARING aRNA AND METHOD FOR ANALYSIS OF GENE EXPRESSION | TORAY INDUSTRIES, INC. (JP) | 2012-08-02 | — | — | US | claimed |
| US-7229765-B2 | Random-primed reverse transcriptase-in vitro transcription method for RNA amplification | ROSETTA INPHARMATICS LLC (US) | 2007-06-12 | — | — | US | claimed |
| US-20040081978-A1 | Random-primed reverse transcriptase-in vitro transcription method for rna amplification | Life Technologies Corporation | 2004-04-29 | — | — | US | claimed |
| WO-2002044399-A2 | IN VITRO TRANSCRIPTION METHOD FOR RNA AMPLIFICATION | ROSETTA INPHARMATICS, INC. (US) | 2002-06-06 | — | — | WO | claimed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | claimed |
| US-20180305768-A1 | DIAGNOSIS AND PROGNOSIS OF BREAST CANCER PATIENTS | THE NETHERLANDS CANCER INSTITUTE (NL) | 2018-10-25 | — | — | US | disclosed |
| US-20180127834-A1 | PREDICTING BREAST CANCER TREATMENT OUTCOME | BIOTHERANOSTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9909185-B2 | Diagnosis and prognosis of breast cancer patients | THE NETHERLANDS CANCER INSTITUTE (NL) | 2018-03-06 | — | — | US | disclosed |
| US-9856533-B2 | Predicting breast cancer treatment outcome | BIOTHERANOSTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | ADISPELL, INC. | 2016-07-07 | — | — | US | disclosed |
| EP-2484760-B1 | METHOD FOR PREPARING aRNA. | TORAY INDUSTRIES (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5683867-A | NUCLEIC ACID LIGANDS, BLENDING, PARTITIONING AND AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5639609-A | HYBRIDIZING WITH CAPTURE PROBE PROTECTED AGAINST ENZYMATIC DEGRADATION | BOEHRINGER MANNHEIM GMBH (DE) | 1997-06-17 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193202-A1 | THERAPEUTIC TREATMENT FOR DRUG POISONING AND ADDICTION | CHRNG, CHRM3, CHRNA5 | P2RY6 1137/4885P2RY2 1153/4885DNPH1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.